The Newswire for Business Lawyers

Sanofi Loses Bid To Stay Launch Of Generic Eloxatin

Law360, New York (July 06, 2009) -- A judge has denied Sanofi-Aventis US LLC's request to stay the launch of generic versions of its popular colon cancer drug Eloxatin pending appeal of a finding of noninfringement in Sanofi's suit against Sandoz Inc., Teva Pharmaceutical Industries Ltd. and others.

Judge Joel Pisano of the U.S. District Court for the District of New Jersey on Wednesday ruled that granting Sanofi's request would be “unwarranted.”...

Login

E-mail
Password
 
  I forgot my login details.

For the whole story, take a 7-day free trial.

Submit your request to try Law360 for free for seven days:

*
*
*
*
*
*
*
*

*Required

Select at least one interest area:*
You will receive Law360's free daily newsletter for the interest area(s) selected..

Appellate
Bankruptcy
Competition
Contract
Corporate Finance
Employment
Energy
Environmental
Financial Services
Health
Insurance
Intellectual Property
International Trade
Product Liability
Securities
Technology
Top News (General Interest)

The only daily news service covering every major practice area of the law.
  • Breaking news available nowhere else
  • More than 66% of articles published before or simultaneously with any other source
  • 63% of articles have critical legal documents attached
  • More than 1,000 columns by leading practitioners published per year
  • More than 20,000 exclusive articles published per year
  • Detailed coverage of 16 major practice areas